Chart Your Path in the Management of AML: Guidance from MD Anderson Expert Faculty
| Overview / Abstract: |
This enhanced digital algorithm combines stepwise practical guidance with evidence-based educational context to deliver an immersive learning opportunity for clinicians who strive to provide their patients with Acute Myeloid Leukemia (AML) the best possible care. The ‘choose your path’ environment allows clinicians to select a clinical area of their interest and navigate AML management based on a patient’s disease status (newly diagnosed or relapsed/refractory) and cytogenetic and molecular profiles, with the help of expert guidance. In the process, current practice guidelines and recent therapy approvals and their supporting data are reviewed, which afford clinicians new therapeutic avenues to enhance the health outcomes of their patients with AML. |
|
Expiration |
Jul 10, 2021 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Monograph |
|
Credits / Hours |
1.0 |
|
Accreditation |
The University of Texas MD Anderson Cancer Center |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Naval Daver, MD |
|
Activity Specialities / Related Topics |
Hematology, Oncology / Cancer / Radiation Therapy, Pathology, Radiology / Imagery / Nuclear Medicine |
|
Sponsors / Supporters / Grant Providers |
Supported by educational grants from AbbVie Inc. and Astellas Pharma Inc. |
|
Keywords / Search Terms |
ACHL CPX-351, liposomal, cytarabine, daunorubicin, chemotherapy, t-AML, SEAMLESS study, Tyrosine kinase inhibitors, CALGB 10603 trial, relapsed AML, refractory AML, Naval Daver, MD, Gilteritinib, ADMIRAL trial, Enasidenib, venetoclax, Ivosidenib, azacytidine, IDH1 mutation, FLT3, NPM1, DNMT3a, IDH1, IDH2, TET2, RUNX1, p53, NRAS, CEBPα, WT1, Midostaurin, Gemtuzumab ozogamicin, Immunophenotyping, cytogenic testing, molecular testing Free CE CME Live CE CME |
|